Global Schizophrenia Drugs Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global schizophrenia drugs market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling. People with schizophrenia require lifelong treatment.
The global schizophrenia drug growth is driven by the increase in the number of patients seeking treatment, and rising demand for improved healthcare infrastructure is expected to drive the market. The schizophrenia market remains replete with strong unmet needs. There is a need for innovation for the treatment of this debilitating disorder.
The increase in the number of patients taking treatment, is expected to drive the growth in the forecast period
Subtle changes in cognition and social relationships are expected to precede the actual diagnosis, often by years. According to the World Health Organization 2019 report, the disease affects 20 million people worldwide. Furthermore, this number is likely to continue to increase, along with the aging population's growth. The increase in the number of patients taking treatment and the rising demand for improved healthcare infrastructure are expected to drive the market. In recent years, the government in several countries has collaborated well with many hospitals across nations to protect people from schizophrenia. The rising burden of the disease and the increasing need to manage it effectively drive the market's growth.
Rising awareness about mental disorders expected to drive the market growth
The increasing cases of mental disorders such as schizophrenia will uplift the global Schizophrenia Drugs Market shares. The surge in medical interventions for treating major mental disorders will enable growth in the global schizophrenia drugs market during the forecast period. Furthermore, the rising emphasis on mental illness and mental health in emerging nations will boost the global Schizophrenia Drugs Market revenue during the forecast period. Moreover, the increasing efficacy and safety features of treatment for schizophrenia will fuel demand among patients, which will accelerate the growth of the global schizophrenia drugs. Schizophrenia is diagnosed 1.4 times more frequently in males than females, as the onset is earlier in men. The peak age of onset is 20-28 years for males and 25-32 years for females.
Currently, 20 products are undergoing clinical trials for the treatment of schizophrenia. Some drugs are expected to aim at new molecular targets for treating unmet needs associated with the disorder. Several market players are expected to serve the unmet market needs, identify new targets, and consequentially develop stronger drug pipelines.
Results from clinical trials of these drugs reported positive top-line primary and secondary endpoint data. Apart from the typical serotonin and dopamine receptors, the drugs are expected to provide novel mechanisms for the treatment of schizophrenia..
Major side effects of drugs is likely to hinder the market growth
However, side effects include bladder disturbances, dermatologic allergic reactions, increased photosensitivity, inhibition of ejaculation, blurred vision, skin pigmentation, ocular opacities, mild fever, nasal congestion, increase in appetite, weight gain, engorgement of the breast with lactation, and menstrual irregularity in female patients. These factors are restricting the growth of the market in the forecast period.
COVID-19 Impact Analysis
The COVID-19 pandemic may have a profound effect on mental health. Those with schizophrenia will affect most. Patients are at higher risk of getting the COVID-19 virus; if being contaminated, what is the expected mortality rate in this patient group? What is the likelihood of suffering from a psychotic relapse due to the situation? According to their findings, schizophrenia patients are at greater infection risk due to their difficulties in following safety procedures. However, schizophrenia patients have deficits in applying adequate hygiene practices mainly because of impaired judgment and self-care.
Approximately 70% of schizophrenia patients suffer from one or more concomitant diseases, and 50-90% of them are regular smokers. Moreover, higher odds of pneumonia and mortality due to immunodeficiency have been suggested in several articles, alongside impaired lung function indications. Regarding the chance of relapse, the COVID-19 can indeed lead indirectly to relapse. These factors are driving the growth of the market in the forecast period.
The second-generation antipsychotics segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
The usual first-line treatment for schizophrenia is an antipsychotic medication. One of the commonly preferred medications is risperidone, also known as a second-generation antipsychotic (SGA) or atypical antipsychotic. Risperidone rebalances dopamine and serotonin to improve thinking, mood, and behavior. It is expected to help in curing some or all of the symptoms of schizophrenia. Moreover, in the United States, the Food and Drug Administration (FDA) approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance (long-term) treatment of the bipolar disorder, and irritability associated with autistic disorders. There are several second-generation drugs available in the market, which are commonly proposed by doctors/physicians. The government's continuous support to private and public healthcare companies also boosts companies' growth in this segment. Therefore, considering the aforementioned reasons, the market for second-generation antipsychotics is likely to grow steadily over the forecast period.
The hospital pharmacy is expected to dominate the schizophrenia drugs during the forecast period
The hospital pharmacies held the largest share in the schizophrenia drugs market. This is mainly due to the increasing number of patients suffering from conditions treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals and adequate reimbursement policies are also contributing to the growth of this segment.
North America region holds the largest market share global schizophrenia drugs
North America region is dominating the global schizophrenia drugs accounted for the largest market share in 2020. The United States accounted for the largest market share in North America region. A major section of the population is approaching such medications therapies, primarily due to hectic lifestyles. Moreover, the country offers highly advanced medical care for early treatment capabilities and government involvement in increasing healthcare expenditure. This factor is driving the market growth in the forecast period.
The schizophrenia drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Sumitomo Dainippon, Eli Lilly, Alkermes, Vanda Pharma, Allergan, and Pfizer. Johnson & Johnson, Otsuka, and Lundbeck among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the schizophrenia drugs globally.
Schizophrenia Drugs Market Key Companies to Watch
Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.
Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.
The global schizophrenia drugs report would provide an access to an approx. 61 market data table, 52 figures and 240 pages.
Global Schizophrenia Drugs Market - By Drug Class
Aristada (Aripiprazole lauroxil)
Global Schizophrenia Drugs Market -By Route of Administration
Global Schizophrenia Drugs Market - By Distribution Channel
Global Schizophrenia Drugs Market - By Region
LIST NOT EXHAUSTIVE